User Experience with Pegcetacoplan On-Body Injector in Patients with C3 Glomerulopathy or Primary Immune-Complex Membranoproliferative Glomerulonephritis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0677; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Interviews from 6 patients or caregivers highlighted that the injector's ease-of-use and portability gave users the freedom to stay active and perform their daily activities at home or away from home while managing their own treatment with confidence. Conclusion The majority of respondents surveyed were satisfied with multiple aspects of their experience with the pegcetacoplan injector for C3G or primary IC-MPGN."
Clinical • Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology
|
|
Abdallah Sassine Geara; Megan Price-Schluns; Mingyi Huang; Jed Perler; Nandini Hadker; Amanda Cassidy Torres; Laura Hill; Nicholas Gonzalez; Katie Gordon
|